natgillin/translations-raw huggingface dataset:
The safety and effectiveness of once every three weeks dosing of Nespo therapy in reducing the requirement for red blood cell transfusions in patients undergoing chemotherapy was assessed in a randomised, double-blind, multinational study. 
Varnost in učinkovitost zdravljenja z Nespom enkrat na tri tedne za zmanjšanje potrebe po transfuzijah eritrocitov so pri bolnikih na kemoterapiji raziskali v randomizirani, dvojno slepi mednarodni študiji.
These antibodies have been shown to cross-react with all erythropoietic proteins, and patients suspected or confirmed to have neutralising antibodies to erythropoietin should not be switched to darbepoetin alfa (see section 4.8). 
Ugotovljeno je, da ta protitelesa navzkrižno reagirajo z vsemi eritropoetičnimi beljakovinami; bolnikov, pri katerih obstaja sum ali pri katerih je potrjeno, da imajo nevtralizirajoča protitelesa proti eritropoetinu, ne smete prevesti na darbepoetin alfa (glejte poglavje 4.8).
Due to its increased carbohydrate content the level of darbepoetin alfa in the circulation remains above the minimum stimulatory concentration for erythropoiesis for longer than the equivalent molar dose of r-HuEPO, allowing darbepoetin alfa to be administered less frequently to achieve the same biological response. 
Zaradi večje vsebnosti ogljikovih hidratov ostane koncentracija darbepoetina alfa v obtoku višja od najmanjše stimulacijske koncentracije za eritropoezo dalj časa kot po enakovrednem molarnem odmerku r-HuEPO; tako je mogoče z manj pogosto uporabo darbepoetina alfa doseči enak biološki
The MAH must ensure that the system of pharmacovigilance, as described in version 3.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market. 
Imetnik dovoljenja za promet mora zagotoviti sistem farmakovigilance (opisan v verziji 3.0, predstavljen v modulu 1.8.1 vloge za pridobitev dovoljenja za promet), ki mora biti vzpostavljen in mora delovati pred časom, ko je zdravilo v prometu, in med časom, ko je v prometu.
• 0.45 micrograms once weekly 
• 0,45 mikrogramov enkrat na teden.
The haemoglobin should be measured every one or two weeks until it is stable. 
Hemoglobin morate kontrolirati na en do dva tedna, dokler vrednost ni stabilna.
Erythropoietin receptors may be expressed on the surface of a variety of tumour cells. 
Eritropoetinski receptorji so lahko izraženi na površini različnih tumorskih celic.
If you have any of these symptoms or you notice any side effects that are not mentioned in this leaflet, please tell your doctor, nurse or pharmacist. 
Če imate katerikoli od teh simptomov ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika, medicinsko sestro ali farmacevta.
Nespo should also be used with caution in those patients with sickle cell anaemia or epilepsy. 
Prav tako morate Nespo uporabljati previdno pri bolnikih z anemijo srpastih celic ali epilepsijo.
Do not inject into areas where the skin is tender, bruised, red, or hard. 
Ne injicirajte v občutljivo, rdečo ali zatrdelo kožo.
If darbepoetin alfa is given concomitantly with any of these drugs, blood levels of these drugs should be monitored and the dosage adjusted as the haemoglobin rises. 
Če darbepoetin alfa dajete sočasno s temi zdravili, je treba njihovo koncentracijo v krvi kontrolirati in odmerke prilagajati, ko se koncentracija hemoglobina zvišuje.
This section contains information on how to properly use the Nespo pre-filled pen. 
To poglavje obsega informacije o pravilni uporabi napolnjenega injekcijskega peresnika Nespo.
D You may hear a second click as the red button pops back up. 
D Ko bo rdeči gumb skočil nazaj navzgor, boste morda slišali drugi klik.
Do not remove the cover from the syringe until you are ready to inject. 
Ne odstranite ovojnine z brizge, dokler niste pripravljeni za injiciranje.
What Nespo is and what is it used for 
KAJ JE ZDRAVILO NESPO IN ZA KAJ GA UPORABLJAMO
D Do maintain pressure on the skin during the injection 
D Med injiciranjem pritiskajte na kožo
If you have forgotten a dose of Nespo, you should contact your doctor to discuss when you should inject the next dose. 
Če ste pozabili odmerek Nespa, se pogovorite z zdravnikom, da vam bo povedal, kdaj si injicirajte
Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to ensure that the lowest approved dose of Nespo is used to maintain haemoglobin at a level that controls the symptoms of anaemia. 
Ko je terapevtski cilj pri posameznem bolniku dosežen, je treba odmerek zmanjšati za 25 do 50 % in tako zagotoviti uporabo najmanjšega odobrenega odmerka Nespa, potrebnega za vzdrževanje takšne koncentracije hemoglobina, ki obvladuje simptome anemije.
A pharmacokinetic study in patients with chemotherapy-induced anaemia treated with 6.75 µg/kg darbepoetin alfa administered SC every 3 weeks in combination with chemotherapy was conducted which allowed for full characterisation of the terminal half-life. 
Farmakokinetična študija, opravljena pri bolnikih z anemijo zaradi kemoterapije, ki so v kombinaciji s kemoterapijo dobivali 6,75 µg/kg darbepoetina alfa subkutano na 3 tedne, je omogočila popolno opredelitev terminalnega razpolovnega časa.
Like all medicines, Nespo may cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Nespo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
(5) Check window 
(5) Preverite okence.
Data from 809 patients receiving Nespo in European clinical studies were analysed to assess the dose required to maintain haemoglobin; no difference was observed between the average weekly dose administered via the intravenous or subcutaneous routes of injection. 
Za določitev odmerka, potrebnega za vzdrževanje hemoglobina, so analizirali 809 bolnikov, ki so Nespo dobivali v evropskih kliničnih študijah; med povprečnim tedenskim odmerkom, uporabljenim intravensko ali subkutano, niso ugotovili razlik.
Compared with pharmacokinetic data from adults with CRF where the same sampling duration was used, the comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF. 
Primerjava s farmakokinetičnimi podatki odraslih bolnikov s kronično boleznijo ledvic, pri katerih je vzorčenje trajalo enako dolgo, je pokazala, da je farmakokinetika darbepoetina alfa pri pediatričnih in odraslih bolnikih s kronično boleznijo ledvic podobna.
These included myelofibrosis and splenic hypertrophy as well as broadening of the ECG-QRS complex in dogs but no dysrhythmia and no effect on the QT interval were observed. 
Med temi učinki so bili mielofibroza, hipertrofija vranice ter razširitev kompleksa QRS na EKG pri psih, vendar brez motenj srčnega ritma
To prepare the area of skin where Nespo will be injected, wipe the injection site with an alcohol wipe. 
Predel kože, v katerega boste injicirali Nespo, pripravite tako, da mesto injiciranja obrišete z alkoholnim lističem.
Adverse reactions were determined based on pooled data from seven randomised, double-blind, placebo-controlled studies of Nespo with a total of 2112 patients (Nespo 1200, placebo 912). 
Neželene učinke so ugotavljali na podlagi kumulativnih podatkov sedmih randomiziranih, dvojno slepih, s placebom kontroliranih študij Nespa pri skupaj 2112 bolnikih (Nespo 1200, placebo 912).
In the event of polycythaemia, Nespo should be temporarily withheld (see section 4.2). 
V primeru policitemije je treba uporabo Nespa prehodno prekiniti (glejte poglavje 4.2).
Paediatric specific PSUR reporting submissions to regulatory authorities will be made every 6 months for the first 2 years following approval of the expanded paediatric indicationfor NESPO in the CKD setting. 
Za pediatrijo specifični PSUR z navedbami predložitev regulatornim organom bo prvi 2 leti po odobritvi razširjene pediatrične indikacije za zdravilo NESPO pri kronični bolezni ledvic pripravljen vsakih 6 mesecev.
This study supports 500 μg once every three weeks being comparable to once weekly administration with respect to the incidence of subjects receiving at least one red blood cell transfusion from week 5 to the end of treatment phase. 
Študija potrjuje, da je uporaba 500 µg enkrat na tri tedne primerljiva uporabi enkrat na teden, kar zadeva incidenco preiskovancev, ki so od 5. tedna do konca terapevtske faze dobili vsaj eno transfuzijo eritrocitov.
When Nespo therapy is absolutely indicated women must stop breast-feeding. 
Če je Nespom absolutno indiciran, mora ženska nehati dojiti.
Patients were randomized to receive Nespo at 500 μg once every three weeks or 2.25 μg /kg once weekly. 
Bolnike so randomizirali na prejemanje Nespa 500 µg enkrat na tri tedne ali 2,25 µg/kg enkrat na teden.
For the upper arms, it is recommended to stretch the skin at the injection site to create a firm and tight surface. 
Na nadlaktu je priporočljivo, da kožo na mestu injiciranja raztegnete in tako ustvarite čvrsto in napeto površino.
Once your anaemia is corrected, your doctor will continue to regularly check your blood and your dose may be adjusted further in order to maintain long-term control of your anaemia. 
Ko bo anemija odpravljena, vam bo zdravnik še naprej redno kontroliral kri in bo morda še naprej prilagajal odmerek, da bo dolgoročno obvladal anemijo.
When changing the route of administration the same dose must be used and the haemoglobin monitored every one or two weeks so that the appropriate dose adjustments can be made to keep the haemoglobin at the desired level. 
Če spremenite pot uporabe, morate uporabiti isti odmerek, hemoglobin pa kontrolirati na en do dva tedna, da boste odmerek lahko prilagajali za ohranitev želene ravni hemoglobina.
In the Nespo group, 83% were receiving dialysis and 17% were not receiving dialysis. 
V skupini, ki je dobivala Nespo, je bilo 83 % bolnikov na dializi, 17% pa ne.
Your normal dialysis routine will not affect the ability of Nespo to treat your anaemia. 
Vaše običajno dializno zdravljenje ne bo vplivalo na učinkovitost Nespa pri zdravljenju anemije.
• If you have symptoms which include unusual tiredness and a lack of energy this could mean you have pure red cell aplasia (PRCA), which has been reported in patients. 
• Če imate simptome, med katerimi sta nenavadna utrujenost in pomanjkanje energije, to lahko pomeni, da imate čisto aplazijo rdečih celic.
Pharmacotherapeutic group: Anti-anaemic ATC Code: B03XA02. 
Oznaka ATC: B03XA02.
Following monthly administration of darbepoetin alfa, at subcutaneous doses ranging from 0.6 to 2.1 µg/kg, the terminal half-life was 73 hours (SD 24). 
Po uporabi darbepoetina alfa enkrat na mesec v subkutanih odmerkih od 0,6 do 2,1 μg/kg je bil terminalni razpolovni čas 73 ur (standardni odklon 24).
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed. 
Zaradi variabilnosti med bolniki se lahko tu in tam pri posameznem bolniku pojavijo vrednosti hemoglobina, ki so višje ali nižje od želene koncentracije.
• Your doctor should try to keep your haemoglobin between 10 and 12 g/dl. 
• Zdravnik si mora prizadevati, da bi vam hemoglobin ohranil med 100 in 120 g/l.
Briefly press and release red button. 
Na kratko pritisnite in spustite rdeči gumb
D Do check the inspection window to confirm it has turned yellow. 
D Poglejte okence in se prepričajte, da je !
• epileptic fits (seizures); 
• epileptične napade (napade krčev),
• Pure red cell aplasia (PRCA) - (anaemia, unusual tiredness, lack of energy) Convulsions (fits and seizures) have been reported in patients treated with Nespo. 
• Čista aplazija rdečih celic - (anemija, nenavadna utrujenost, pomanjkanje energije) Pri bolnikih, zdravljenih z Nespom, so bile opisane konvulzije (napadi krčev).
Nespo (SureClick) is supplied ready for use in a pre-filled pen. 
Nespo (SureClick) je na voljo pripravljen za uporabo v napolnjenih injekcijskih peresnikih.
Your doctor has given you Nespo (an anti-anaemic) to treat your anaemia. 
Zdravnik vam je predpisal Nespo (zdravilo proti slabokrvnosti) za zdravljenje anemije.
Supplementary iron therapy is recommended for all patients with serum ferritin values below 100 µg/l or whose transferrin saturation is below 20%. 
Dodatna terapija z železom je priporočljiva pri vseh bolnikih, ki imajo feritin v serumu pod 100 µg/l
• if you have been diagnosed with high blood pressure which is not being controlled with other medicines prescribed by your doctor; or 
• če imate ugotovljen visok krvni tlak in ta ni obvladan z drugimi zdravili, ki vam jih je predpisal
Stretch the skin on alternate injection sites 
Raztegnite kožo na drugih možnih mestih injiciranja.
Nespo is supplied in vials. 
Nespo je na voljo v vialah.
Nespo (SureClick) comes in a pre-filled pen that contains either 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 or 500 micrograms of the active substance darbepoetin alfa. 
Nespo (SureClick) je na voljo v napolnjenih injekcijskih peresnikih, ki vsebujejo 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 ali 500 mikrogramov zdravilne učinkovine darbepoetina alfa.
Appropriate dose titration between 500 μg, 300 μg, and 150 μg should be considered. 
V poštev pride ustrezno titriranje odmerka med 500 µg, 300 µg in 150 µg.
Your doctor will tell you how much and how often you must take Nespoin order to maintain a haemoglobin level between 10 and 12 g/dl. 
Zdravnik vam bo povedal, koliko Nespa morate uporabljati in kako pogosto, da boste koncentracijo hemoglobina ohranili med 100 in 120 g/l.
Nespo comes in a pre-filled syringe that contains either 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 or 500 micrograms of the active substance darbepoetin alfa. 
Nespo je na voljo v napolnjenih injekcijskih brizgah, ki vsebujejo 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 ali 500 mikrogramov zdravilne učinkovine darbepoetina alfa.
The extent to which these outcomes might apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/dl, is unclear because few patients with these characteristics were included in the data reviewed. 
Ni pa jasno, v kolikšni meri bi te ugotovitve lahko veljale za uporabo rekombinantnega eritropoetina pri bolnikih z rakom, ki dobivajo kemoterapijo, če je ciljna koncentracija hemoglobina manjša od 130 g/l; analizirani podatki so namreč obsegali le malo bolnikov
Nespo is given as a single injection, either once a week, once every two weeks, or once every month either under your skin (subcutaneous) or into a vein (intravenous). 
Nespo vbrizgamo v eni injekciji, bodisi enkrat na teden, enkrat na dva tedna, ali enkrat na mesec, in sicer pod kožo (subkutano) ali v veno (intravensko).
After any dose or schedule adjustment the haemoglobin should be monitored every one or two weeks. 
Po vsaki prilagoditvi odmerka ali sheme morate hemoglobin kontrolirati na en do dva tedna.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.375 ml OTHER Dompé Biotec S.p.A. 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 0,375 ml DRUGI PODATKI Dompé Biotec S.p.A.
HOW TO USE THE NESPO PRE-FILLED PEN (SURECLICK) 
KAKO UPORABLJATI NAPOLNJENI INJEKCIJSKI PERESNIK (SURECLICK)
Instructions for preferred injection site 
Navodila za prednostno mesto injiciranja
• NEVER put the grey needle cap back into the used pre-filled pen. 
• Sivega pokrovčka igle NIKOLI ne nataknite nazaj na rabljeni napolnjeni injekcijski peresnik.
• 2.25 micrograms (once weekly) of Nespo per kilogram of your body weight. 
• 2,25 mikrogramov (enkrat na teden) Nespa na kilogram telesne mase.
Store in a refrigerator (2°C - 8°C). 
Shranjujte v hladilniku (med 2 °C in 8 °C).
Release button 
Sprožilni gumb
• 500 micrograms once every three weeks (6.75 micrograms of Nespo per kilogram of your body weight), or 
• 500 mikrogramov enkrat na tri tedne (6,75 mikrogramov Nespa na kilogram telesne mase enkrat na tri tedne) ali
• Blood clots (thrombosis) 
• Krvni strdki (tromboza)
Patients with solid tumours (e.g., lung, breast, colon, ovarian cancers) and lymphoid malignancies (e.g., lymphoma, multiple myeloma) were enrolled in the clinical studies. 
Te klinične študije so vključile bolnike s čvrstimi tumorji (npr. rakom pljuč, dojke, kolona, jajčnika) in limfatičnimi malignomi (npr. limfomom, multiplim mielomom).
If you forget to inject Nespo 
Če ste pozabili vzeti zdravilo Nespo
Nespo SureClick Pre-filled pen - Read package leaflet before use Preferred site is front of the thigh 
Nespo SureClick napolnjeni injekcijski peresnik - Pred uporabo natančno preberite navodilo za
Remember: If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. 
Ne pozabite: če imate kakršnekoli težave, brez obotavljanja prosite za pomoč in nasvet zdravnika ali medicinsko sestro.
Nespo 10 micrograms solution for injection in a pre-filled syringe Nespo 15 micrograms solution for injection in a pre-filled syringe Nespo 20 micrograms solution for injection in a pre-filled syringe Nespo 30 micrograms solution for injection in a pre-filled syringe Nespo 40 micrograms solution for injection in a pre-filled syringe Nespo 50 micrograms solution for injection in a pre-filled syringe Nespo 60 micrograms solution for injection in a pre-filled syringe Nespo 80 micrograms solution for injection in a pre-filled syringe Nespo 100 micrograms solution for injection in a pre-filled syringe Nespo 130 micrograms solution for injection in a pre-filled syringe Nespo 150 micrograms solution for injection in a pre-filled syringe Nespo 300 micrograms solution for injection in a pre-filled syringe Nespo 500 micrograms solution for injection in a pre-filled syringe 
NAVODILO ZA UPORABO Nespo 10 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 15 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 20 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 30 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 40 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 50 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 60 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 80 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 100 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 130 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 150 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 300 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi Nespo 500 mikrogramov raztopina za injiciranje v napolnjeni injekcijski brizgi
• liver disease; 
• bolezen jeter,
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/ 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA)
What Nespo looks like and contents of the pack 
Izgled zdravila Nespo in vsebina pakiranja
The vials are made from type 1 glass with fluoropolymer coated rubber stoppers. 
Viale so iz stekla tipa I in imajo gumijaste zamaške, prekrite s fluoropolimerom.
• If you have chronic renal failure there is an increased risk of serious problems with your heart or blood vessels (cardiovascular events) if your haemoglobin is kept too high. 
• Če imate kronično odpoved ledvic in ves čas previsoko koncentracijo hemoglobina, obstaja večje tveganje za resne težave s srcem ali ožiljem (srčnožilne dogodke).
The injection site must be firm for the device to work properly. 
Za pravilno delovanje pripomočka mora biti mesto injiciranja čvrsto.
Any medicinal product remaining in the vial should be disposed of. 
Ostanek zdravila v viali morate zavreči.
The Nespo (SureClick) pre-filled pen delivers the complete dose of each presentation. 
Napolnjeni injekcijski peresnik Nespo (SureClick) aplicira celoten odmerek posamezne jakosti.
Remove the pen from the refrigerator. 
Vzemite injekcijski peresnik iz hladilnika.
If you want more information about this medicine, please contact the local representative of the company that is authorised to market Nespo. 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
• significant lack of response to drugs used to treat anaemia; or 
• izrazito neodzivnost na zdravila za zdravljenje anemije ali
For a more comfortable injection, leave the pen at room temperature for approximately 30 minutes. 
Da injiciranje ne bo neprijetno, pustite injekcijski peresnik približno 30 minut na sobni temperaturi.
For paediatric patients ≥ 11 years of age, in the maintenance phase, Nespo may continue to be administered as a single injection once weekly or once every two weeks. 
Pri pediatričnih bolnikih, starih ≥ 11 let, lahko Nespo med obdobjem vzdrževanja še naprej uporabljate v eni injekciji enkrat na teden ali enkrat na dva tedna.
Following subcutaneous administration of 2.25 µg/kg to adult cancer patients a mean peak concentration of 10.6 ng/ml (SD 5.9) of darbepoetin alfa was reached at a mean time of 91 hours (SD 19.7). 
Pri odraslih onkoloških bolnikih je darbepoetin alfa po subkutani uporabi 2,25 µg/kg dosegel povprečno največjo koncentracijo 10,6 ng/ml (standardni odklon 5,9) v povprečno 91 urah (standardni odklon 19,7).
Only use each pre-filled pen for one injection. 
Vsak napolnjeni injekcijski peresnik uporabite le za eno injiciranje.
Nespo 10 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 15 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 20 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 30 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 40 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 50 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 60 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 80 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 100 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 130 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 150 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 300 micrograms solution for injection in a pre-filled pen (SureClick) Nespo 500 micrograms solution for injection in a pre-filled pen (SureClick) 
NAVODILO ZA UPORABO Nespo 10 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku (SureClick) Nespo 15 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku (SureClick) Nespo 20 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku (SureClick) Nespo 30 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku (SureClick) Nespo 40 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 50 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 60 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 80 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 100 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 130 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 150 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 300 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Nespo 500 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku
Do not administer more than one dose per vial. 
Iz ene viale ne aplicirajte več kot enega odmerka.
The recommended initial dose is 500 μg (6.75 μg/kg) given once every three weeks, or once weekly dosing can be given at 2.25 μg/kg body weight. 
Priporočeni začetni odmerek je 500 µg (6,75 µg/kg) enkrat na tri tedne, uporabiti pa je mogoče tudi odmerjanje 2,25 µg/kg telesne mase enkrat na teden.